skip to primary navigationskip to content
 

PolyProx Therapeutics raises £3.4m seed financing to validate novel class of cancer drugs

last modified May 01, 2019 08:22 AM
A spin out of the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a decade of research and intellectual property from founder Professor Laura Itzhaki’s laboratory...

A spin out of the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a decade of research and intellectual property from founder Professor Laura Itzhaki’s laboratory working closely with co-founders Dr Albert Perez-Riba and Dr Pamela Rowling and with other members of the Itzhaki group.

PolyProx Therapeutics will develop a new class of drugs, called Polyproxin™ molecules, that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.

Polyproxin™ molecules target disease-causing proteins within tumour cells and trigger pathways to eliminate these proteins, thereby halting further growth of the tumour.  This approach has the potential to address cancer targets that have proven untreatable using current technologies, important in major diseases such as lung, colorectal and pancreatic cancers. The technology behind this approach uses protein scaffolds to link a targeting entity at one end and a degradation trigger at the other, assembled in such a way as to allow access to the tumour cell and recyclable activity.

More details: www.polyprox.com and https://www.cambridgenetwork.co.uk/news/polyprox-therapeutics-3pt4mgbp-seed-financing-cancer-drugs/

« May 2021 »
May
MoTuWeThFrSaSu
12
3456789
10111213141516
17181920212223
24252627282930
31

Proud holders of Athena SWAN Bronze

Athenaswan

RSS Feed Latest news

Naked Mole Ravolt

May 06, 2021

In work funded by the Dunhill Medical Trust, Dr Ewan St. John Smith has made a series of animations with ScienceSplained....

Nature Photography Competition

Apr 27, 2021

For Mental Health Awareness Week 10th to 16th of May 2021 the Department of Pharmacology Equality, Diversity and Wellbeing Committee is running a Nature Photography Competition...

Designer proteins to seek and destroy

Apr 16, 2021

A new BBSRC-funded project aims to exploit de novo designed proteins to control protein-protein interactions in new ways...

Dr Matt Harris

Apr 15, 2021

Congratulations to Dr Matt Harris...

GRC Connects

Apr 08, 2021

GRC Connects: Multi-Drug Efflux Systems Efflux Pumps at the Forefront of Antibiotic Resistance and Pharmacotherapy in a Global Health Crisis...

View all news